📰 Thomas Biegi News
Page 2 - Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
December 11, 2023
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in...
November 21, 2023
EQS-News: MorphoSys AG / Key word(s): Study resultsMorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction 20.11.2023 / 22:29 CET/CESTThe issuer is solely responsible for the content of this a...
November 16, 2023
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results 15.11.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 15, 2023 MorphoSys AG...
November 2, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting 02.11.2023 / 14:05 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, Novemb...
October 25, 2023
EQS-News: MorphoSys AG / Key word: Change in Forecast MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023...
October 25, 2023
EQS-News: MorphoSys AG / Key word(s): Change in Forecast MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross ...
October 25, 2023
EQS-News: MorphoSys AG / Key word(s): Change in ForecastMorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023 25.10.2023 / 10:50 CET/CESTThe issuer is solely responsible for the content of this announcement.Planegg/Munich, Germany, October 25, 2023 Mo...
September 13, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, September 12, 2023 MorphoSys Receiv...
September 12, 2023
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmime...
September 12, 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer 12.09.2023 / 22:01...